再次外科主动脉瓣置换与瓣中瓣经导管主动脉瓣置换治疗退化生物瓣的长期结局比较
本研究基于美国Medicare数据库,采用1:1倾向性评分匹配比较再次外科主动脉瓣置换(redo-SAVR)与瓣中瓣经导管主动脉瓣置换(ViV-TAVR)治疗退化生物瓣的长期结局。匹配后各1256例,redo-SAVR组主要不良心血管事件较高(17.4% vs 13.1%;P = .003),但5年生存率(62.3% vs 46.7%;P < .001)及无主要瓣膜事件生存期更优。结论提示redo-SAVR虽围术期并发症较多,但长期生存可能优于ViV-TAVR。
要点
- 匹配队列中redo-SAVR的5年生存率显著高于ViV-TAVR(62.3% vs 46.7%;P < .001)。
- redo-SAVR主要不良心血管事件发生率较高(17.4% vs 13.1%;P = .003)。
- redo-SAVR无主要瓣膜事件生存期更长(71个月 vs 43个月;P < .001)。
核心结论
- redo-SAVR可能较ViV-TAVR具有更好的长期生存,尽管围术期并发症更多。
- 需临床试验数据以指导退化生物瓣再干预的临床决策,尤其对预期寿命合理的患者。
研究设计与样本
- 回顾性队列研究,使用美国Medicare受益人数据,纳入2011年9月29日至2020年12月30日因退化生物瓣入院并接受redo-SAVR或ViV-TAVR的患者。
- 采用1:1倾向性评分匹配,排除心内膜炎、同期其他心脏手术及同次住院期间主动脉瓣再干预者。
- 主要结局为5年生存,次要复合结局包括主要不良心血管事件(30天手术死亡、卒中或急性心肌梗死)和无主要瓣膜事件生存(心力衰竭再入院、心内膜炎或主动脉瓣再干预)。
主要发现
- 总体识别4699例患者,其中redo-SAVR 1775例,ViV-TAVR 2924例;redo-SAVR组更年轻(中位72 vs 79岁),充血性心力衰竭(39.6% vs 68.8%)及既往冠状动脉旁路移植史(17.9% vs 32.0%)比例更低(所有P < .05)。
- 倾向性评分匹配后各1256例,redo-SAVR组主要不良心血管事件较高(17.4% vs 13.1%;P = .003)。
- redo-SAVR组无主要瓣膜事件生存期更长(71 [62-79]个月 vs 43 [38-47]个月;P < .001),5年生存率更高(62.3% vs 46.7%;P < .001)。
- 按Charlson合并症指数分层后,redo-SAVR的长期生存获益在较低风险(67.6% vs 54.9%;P = .001)和中高风险(55.1% vs 36.7%;P < .001)患者中均持续存在。
临床怎么用
- 对于退化生物瓣再干预患者,尤其预期寿命合理者,redo-SAVR可能提供更好的长期生存,但需权衡其较高的围术期并发症风险。
- 临床决策应结合患者年龄、合并症及风险分层个体化选择redo-SAVR或ViV-TAVR。
局限性
- 原文未明确说明局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is associated with improved perioperative safety compared with redo surgical aortic valve replacement (redo-SAVR), but long-term outcomes remain uncertain. We therefore compare long-term outcomes of ViV-TAVR and redo-SAVR. METHODS: The study included 1:1 propensity score-matched Medicare beneficiaries with degenerated bioprosthetic valves admitted between September 29, 2011, and December 30, 2020, undergoing either redo-SAVR or ViV-TAVR. Exclusion criteria included endocarditis, other concomitant cardiac surgery, and aortic valve reintervention during the same admission. The primary outcome was 5-year survival. Composite secondary outcomes included major adverse cardiovascular events (30-day operative mortality, stroke, or acute myocardial infarction) and major valve event-free survival (congestive heart failure readmission, endocarditis, or aortic valve reintervention). Time-to-event analyses used Kaplan-Meier analysis and multivariable Cox proportional hazards modeling. RESULTS: Overall, 4699 patients, including 1775 redo-SAVR and 2924 ViV-TAVR patients, were identified. Redo-SAVR patients were younger (median [interquartile range], 72 [68-77] years vs 79 [73-84] years) with less congestive heart failure (39.6% vs 68.8%) and prior coronary artery bypass grafting (17.9% vs 32.0%; all P < .05). In the propensity score-matched cohorts of 1256 patients each, redo-SAVR had higher major adverse cardiovascular events (17.4% vs 13.1%; P = .003) but better major valve event-free (71 [62-79] months vs 43 [38-47] months; P < .001) and 5-year (62.3% vs 46.7%; P < .001) survival. After stratification by Charlson comorbidity index, the long-term survival benefit persisted in patients of lower (67.6% vs 54.9%; P = .001) and medium or higher risk (55.1% vs 36.7%; P < .001). CONCLUSIONS: Redo-SAVR may have better long-term survival than ViV-TAVR despite greater perioperative morbidity. Clinical trial data are needed to fully inform clinical decision-making about degenerated bioprosthetic valve reintervention, particularly for patients with reasonable life expectancy.
引用
- Awtry J, Faggion Vinholo T, Cho M, et al. Redo Surgical Aortic Valve Replacement vs Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprosthetic Valves. Ann Thorac Surg. 2025. PMID: 39864775. doi:10.1016/j.athoracsur.2025.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。